Summer Savings! Get unlimited digital access for 13 weeks for $13.
Topics

Food and Drug Administration

Sales of MannKind's inhaled insulin continue slow start

Sales of MannKind's inhaled insulin continue slow start

MannKind Corp.’s inhaled insulin drug Afrezza continued its slow launch in the second quarter of the year. Sanofi, the French pharmaceutical company that’s selling Afrezza in a partnership agreement with MannKind, said it sold just $2.2 million of the drug in the quarter that ended June 30. That means that in its first five months, sales have reached just $3.3 million – a disappointing result considering some analysts expect sales to reach $1 billion a year. MannKind’s stock was down just 1 cent to $4.43 at 12:15 p.m. Pacific time. It initially fell 10%, but rebounded later in the trading session. Matthew Pfeffer, MannKind’s chief financial officer, said...

Loading
81°